drugset / Trial / NCT02567331
A Study of Capecitabine (Xeloda) in Patients With Metastatic Colorectal Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study will evaluate the efficacy, safety, and pharmacoeconomics of oral capecitabine in patients with metastatic colorectal cancer. The anticipated time on study treatment is 3-12 months, and the target sample size is 28 individuals.
Timeline
- Start
- 2004-10
- Primary completion
- 2006-04
- Completion
- 2006-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1250 mg/m2 | Oral |